title: A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.
abstract: BACKGROUND
  Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).
  
  
  METHODS
  Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.
  
  
  RESULTS
  Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).
  
  
  CONCLUSIONS
  In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.
authors.affiliation: Cork Adult Cystic Fibrosis Centre, University College Cork, Cork University Hospital, Cork, Ireland. Electronic address: b.plant@ucc.ie.
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Plant
authors.affiliation: Belfast Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK.
authors.forename: Damian G
authors.initials: DG
authors.lastname: Downey
authors.affiliation: Cork Adult Cystic Fibrosis Centre, University College Cork, Cork University Hospital, Cork, Ireland.
authors.forename: Joe A
authors.initials: JA
authors.lastname: Eustace
authors.affiliation: Cystic Fibrosis Unit, Beaumont Hospital, Dublin, Ireland.
authors.forename: Cedric
authors.initials: C
authors.lastname: Gunaratnam
authors.affiliation: Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK.
authors.forename: Charles S
authors.initials: CS
authors.lastname: Haworth
authors.affiliation: Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester, Manchester, UK.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Jones
authors.affiliation: Department of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.
authors.forename: Edward F
authors.initials: EF
authors.lastname: McKone
authors.affiliation: Regional Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds, UK.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Peckham
authors.affiliation: All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Cardiff, UK.
authors.forename: R Ian
authors.initials: RI
authors.lastname: Ketchell
authors.affiliation: Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.
authors.forename: Diana
authors.initials: D
authors.lastname: Bilton
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001398:Aztreonam / Q000008:administration & dosage*; D015992:Body Mass Index; D003550:Cystic Fibrosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008239:Lysine / Q000008:administration & dosage*; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000209:etiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012129:Respiratory Function Tests / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001398:Aztreonam; D008239:Lysine
keywords: Aztreonam; Cystic fibrosis; Evaluation tool; Forced expiratory volume; Intravenous antibiotics